MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

118.64
-2.18
-1.80%
Opening 15:50 01/20 EST
OPEN
123.15
PREV CLOSE
120.81
HIGH
124.82
LOW
117.91
VOLUME
333.90K
TURNOVER
--
52 WEEK HIGH
225.47
52 WEEK LOW
115.57
MARKET CAP
6.55B
P/E (TTM)
-12.4428
1D
5D
1M
3M
1Y
5Y
Should Investors Worry About Mirati Therapeutics Inc's Insider Sells?
GuruFocus data shows that EVP Chief Commercial Officer Benjamin Hickey has sold 627 shares in Mirati Therapeutics Inc ( NA:MRTX), on 2022-01-18.
GuruFocus.com · 10h ago
BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
Zacks · 6d ago
Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU
Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.
Zacks · 01/10 15:19
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022. David Meek, chief executive offic...
PR Newswire · 01/04 21:30
MainStay VP Wellington Mid Cap Portfolio Buys Icon PLC, Digital Turbine Inc, Integra ...
Investment company MainStay VP Wellington Mid Cap Portfolio (Current Portfolio) buys Icon PLC, Digital Turbine Inc, Integra Lifesciences Holdings Corp, Ultragenyx Pharmaceutical Inc, Denny's Corp, sells Hill-Rom Holdings Inc, Amedisys Inc, Carter's Inc, Bl...
GuruFocus.com · 12/23/2021 12:38
Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have
Seekingalpha · 12/19/2021 14:00
Glenview Capital Management Buys Willis Towers Watson PLC, Uber Technologies Inc, Baxter ...
Investment company Glenview Capital Management (Current Portfolio) buys Willis Towers Watson PLC, Uber Technologies Inc, Baxter International Inc, Global Payments Inc, Aptiv PLC, sells Walgreens Boots Alliance Inc, ViacomCBS Inc, Amazon.com Inc, DXC Techno...
GuruFocus.com · 12/14/2021 04:38
Inv Corp Small Cap Growth Buys Zuora Inc, Ollie's Bargain Outlet Holdings Inc, Sonic Automotive ...
Investment company Inv Corp Small Cap Growth (Current Portfolio) buys Zuora Inc, Ollie's Bargain Outlet Holdings Inc, Sonic Automotive Inc, Rent-A-Center Inc, Bloomin Brands Inc, sells Redfin Corp, Skyline Champion Corp, Mirati Therapeutics Inc, Synaptics ...
GuruFocus.com · 12/08/2021 23:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
43.75%Buy
25.00%Hold
6.25%Under-perform
0.00%Sell
Analyst Price Target
The average MRTX stock price target is 220.08 with a high estimate of 300.00 and a low estimate of 171.00.
High300.00
Average220.08
Low171.00
Current 118.64
EPS
Actual
Estimate
-2.58-1.94-1.29-0.65
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 308
Institutional Holdings: 63.95M
% Owned: 115.81%
Shares Outstanding: 55.22M
TypeInstitutionsShares
Increased
89
4.27M
New
41
790.98K
Decreased
79
3.04M
Sold Out
46
663.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.37%
Key Executives
Chairman/Director
Faheem Hasnain
President
Charles Baum
Chief Executive Officer
David Meek
Chief Financial Officer
Vickie Reed
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Independent Director
Bruce Carter
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
Independent Director
Shalini Sharp
No Data
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.